Buy These Defensive Stocks After Beating Earnings Expectations?: ACI, JNJZacks Investment Research • 04/16/25
Johnson & Johnson to Participate in the 2025 RBC Capital Markets Global Healthcare ConferenceBusiness Wire • 04/16/25
Healthy Returns: What drugmakers are saying about Trump's looming pharmaceutical tariffsCNBC • 04/16/25
J&J's Spravato momentum points to commercial viability of psychedelics for mental health, analysts sayProactive Investors • 04/15/25
Two New Dividend Picks To Help You Navigate Tariffs And Uncertainty -- One Yields 7%+Seeking Alpha • 04/15/25
JNJ Tops Q1 Earnings, Ups '25 Sales View to Include Intra-Cellular DealZacks Investment Research • 04/15/25
Import Prices, Empire State Come In Mild; Q1 Earnings Beats AboundZacks Investment Research • 04/15/25
Johnson & Johnson: First Look At Q1 Earnings - Solid Quarter Will Calm NervesSeeking Alpha • 04/15/25
Compared to Estimates, Johnson & Johnson (JNJ) Q1 Earnings: A Look at Key MetricsZacks Investment Research • 04/15/25
Johnson & Johnson Skids Despite First-Quarter Beat, Sales Guidance HikeInvestors Business Daily • 04/15/25
Johnson & Johnson Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate AnalystsBenzinga • 04/15/25
Johnson & Johnson's Oral IL-23, Icotrokinra, Poised to Redefine the Psoriasis Treatment Landscape Following Positive Phase 3 Data, According to Spherix Global InsightsGlobeNewsWire • 04/14/25